Your browser doesn't support javascript.
loading
Prevalence of the apolipoprotein E ε4 allele in amyloid ß positive subjects across the spectrum of Alzheimer's disease.
Mattsson, Niklas; Groot, Colin; Jansen, Willemijn J; Landau, Susan M; Villemagne, Victor L; Engelborghs, Sebastiaan; Mintun, Mark M; Lleo, Alberto; Molinuevo, José Luis; Jagust, William J; Frisoni, Giovanni B; Ivanoiu, Adrian; Chételat, Gaël; Resende de Oliveira, Catarina; Rodrigue, Karen M; Kornhuber, Johannes; Wallin, Anders; Klimkowicz-Mrowiec, Aleksandra; Kandimalla, Ramesh; Popp, Julius; Aalten, Pauline P; Aarsland, Dag; Alcolea, Daniel; Almdahl, Ina S; Baldeiras, Inês; van Buchem, Mark A; Cavedo, Enrica; Chen, Kewei; Cohen, Ann D; Förster, Stefan; Fortea, Juan; Frederiksen, Kristian S; Freund-Levi, Yvonne; Gill, Kiran Dip; Gkatzima, Olymbia; Grimmer, Timo; Hampel, Harald; Herukka, Sanna-Kaisa; Johannsen, Peter; van Laere, Koen; de Leon, Mony J; Maier, Wolfgang; Marcusson, Jan; Meulenbroek, Olga; Møllergård, Hanne M; Morris, John C; Mroczko, Barbara; Nordlund, Arto; Prabhakar, Sudesh; Peters, Oliver.
Afiliação
  • Mattsson N; Clinical Memory Research Unit, Clinical Sciences Malmö, Lund University, Lund, Sweden. Electronic address: niklas.mattsson@med.lu.se.
  • Groot C; Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands.
  • Jansen WJ; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.
  • Landau SM; Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA.
  • Villemagne VL; Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia.
  • Engelborghs S; Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.
  • Mintun MM; Avid Radiopharmaceuticals, Philadelphia, PA, USA.
  • Lleo A; Neurology Department, Hospital de Sant Pau, Barcelona, Spain.
  • Molinuevo JL; Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain.
  • Jagust WJ; Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA.
  • Frisoni GB; Memory Clinic and LANVIE- Laboratory of Neuroimaging of Aging, University Hospitals, and University of Geneva, Geneva, Switzerland; Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Ivanoiu A; Memory Clinic and Neurochemistry Laboratory, Saint Luc University Hospital, Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium.
  • Chételat G; Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France.
  • Resende de Oliveira C; Center for Neuroscience and Cell Biology, Faculty of Medicine, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
  • Rodrigue KM; Center for Vital Longevity, School of Behavioral and Brain Sciences, The University of Texas at Dallas, Dallas, TX, USA.
  • Kornhuber J; Department of Psychiatry and Psychotherapy, Friedrich-Alexander University of Erlangen- Nuremberg, Erlangen, Germany.
  • Wallin A; Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
  • Klimkowicz-Mrowiec A; Jagiellonian University College of Medicine, Krakow, Poland.
  • Kandimalla R; Department of Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Popp J; Department of Psychiatry, Service of Old Age Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland.
  • Aalten PP; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands.
  • Aarsland D; Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
  • Alcolea D; Neurology Department, Hospital de Sant Pau, Barcelona, Spain.
  • Almdahl IS; Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
  • Baldeiras I; Center for Neuroscience and Cell Biology, Faculty of Medicine, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
  • van Buchem MA; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Cavedo E; Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; AXA Research Fund & UPMC Chair, Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Dé
  • Chen K; Banner Alzheimer's Institute, Phoenix, AZ, USA.
  • Cohen AD; University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, PA, USA.
  • Förster S; Department of Nuclear Medicine, Technische Universitaet München, Munich, Germany.
  • Fortea J; Neurology Department, Hospital de Sant Pau, Barcelona, Spain.
  • Frederiksen KS; Danish Dementia Research Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Freund-Levi Y; Department of Geriatrics, Karolinska University Hospital Huddinge, Section of Clinical Geriatrics, Institution of NVS, Karolinska Institutet, Stockholm, Sweden.
  • Gill KD; Department of Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Gkatzima O; Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Grimmer T; Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitaet München, Munich, Germany.
  • Hampel H; AXA Research Fund & UPMC Chair, Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Paris, Franc
  • Herukka SK; Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
  • Johannsen P; Memory Clinic, Danish Dementia Research Center, Rigshospitalet, Copenhagen, Denmark.
  • van Laere K; Department of Imaging and Pathology, Catholic University Leuven, Leuven, Belgium.
  • de Leon MJ; School of Medicine, Center for Brain Health, New York University, New York, NY, USA.
  • Maier W; Department of Psychiatry and Psychotherapy, University of Bonn, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Marcusson J; Geriatric Medicine, Department of Clinical and Experimental Medicine, University of Linköping, Linköping, Sweden.
  • Meulenbroek O; Department of Geriatric Medicine, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Møllergård HM; Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
  • Morris JC; Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.
  • Mroczko B; Department of Neurodegeneration Diagnostics, Leading National Research Centre in Bialystok (KNOW), Medical University of Bialystok, Bialystok, Poland.
  • Nordlund A; Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
  • Prabhakar S; Department of Neurology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Peters O; Department of Psychiatry and Psychotherapy, Charité Berlin, German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Alzheimers Dement ; 14(7): 913-924, 2018 07.
Article em En | MEDLINE | ID: mdl-29601787
INTRODUCTION: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid ß (Aß) pathology. METHODS: We included 3451 Aß+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location. RESULTS: The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aß+ cognitively normal and Aß+ mild cognitive impairment (P < .05) but not in Aß+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education. DISCUSSION: The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aß pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Apolipoproteína E4 / Doença de Alzheimer / Disfunção Cognitiva Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos beta-Amiloides / Apolipoproteína E4 / Doença de Alzheimer / Disfunção Cognitiva Idioma: En Ano de publicação: 2018 Tipo de documento: Article